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Abstract
Background: We report herein a rare case of primary omental gastrointestinal stromal tumor
(GIST).
Case presentation: A 65 year-old man was referred to our hospital with a huge abdominal mass
occupying the entire left upper abdomen as shown by sonography. On computed tomography
(CT), this appeared as a heterogeneous low-density mass with faint enhancement. Abdominal
angiography revealed that the right gastroepiploic artery supplied the tumor. With such an
indication of gastric GIST, liposarcoma, leiomyosarcoma or mesothelioma laparotomy was
performed and revealed that this large mass measured 20 × 17 × 6 cm, arising from the greater
omentum. It was completely resected. Histopathologically, it was composed of proliferating spindle
and epithelioid cells with an interlacing bundle pattern. Immunohistochemically, the tumor was
positive for myeloid stem cell antigen (CD34), weakly positive for c-KIT (CD117) and slightly
positive for neuron-specific enolase (NSE), but negative for cytokeratin (CK), alpha-smooth muscle
actin (SMA) and S-100 protein. A mutation was identified in the platelet-derived growth factor
alpha (PDGFRA) juxtamembrane domain (exon 12, codon561) and the tumor was diagnosed as an
omental GIST. The postoperative course was uneventful. The patient is treated by Glevec® and is
alive well with no sign of relapse.
Conclusion: Our case demonstrated a weak immunohistochemical expression of c-kit (CD117)
and a point mutation in PDGFRA exon 12 resulting in an Asp for Val561 substitution. Imatinib
therapy as an adjuvant to complete resection has been carried out safely. Because of the rarity of
primary omental GISTs, it is inevitable to analyze accumulating data from case reports for a better
and more detailed understanding of primary omental GISTs.
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GISTs are mesenchymal tumors, the majority of which is
KIT (CD117)-positive, typically arising in association
with the muscularis propria of the gastrointestinal tract
wall. Accordingly, they occur most frequently in the stom-
ach (60%), jejunum and ileum (30%), and less frequently
in the duodenum (5%), < 5% colorectal < 1% in the
esophagus and appendix [1]. A small number may origi-
nate not from the omentum, but from outside the gas-
trointestinal tract; these are designated extra-GISTs
(EGISTs)[2]. To the best of our knowledge, thus far only
28 cases of primary omental GISTs, including that
described in the present study, have been reported. His-
topathologic and immunohistochemical characteristics of
EGISTs are similar to GISTs, the majority of both having
mutually exclusive gain-of-function KIT/PDGFRA muta-
tions. However, because of the rarity of the omental
GISTs, it is difficult to assess their malignant potential,
prognostic factors or efficacy of surgery alone or in combi-
nation with molecular targeting chemotherapy with the
Kit/PDGFRA tyrosine kinase inhibitor Imatinib, and their
overall prognosis.
Here, we report a rare case of primary omental myxoid
epithelioid GIST which we have characterized immuno-
histochemically and genetically. We review the English-
language literature on primary omental GISTs.
Case presentation
A 65-year-old man was referred to our hospital in October
2006 with a huge abdominal tumor. A firm mass was pal-
pated extending from the epigastrium to the left hypogas-
trium. There were no laboratory abnormalities, except a
slight elevation of the total bilirubin (1.3 mg/dl) and lac-
tate dehydrogenase (LDH: 217 IU/L) levels in the serum.
The tumor markers carcinoembryonic antigen (CEA) and
carbohydrate antigen (CA19-9) were within the normal
range. Ultrasonography showed that the mass occupied
almost the entire upper abdomen anterior to the bowel
loops. On computed tomography (CT), a mass behind the
left hepatic lobe showed heterogeneous low density with
faint enhancement (Fig. 1). Abdominal angiography
revealed that the tumor was vascularized mainly from the
right epigastric artery (Fig. 2). We suspected liposarcoma,
leiomyosarcoma, mesothelioma, or gastric GIST. At
laparotomy on October 2006, a well-encapsulated tumor
was found in the greater omentum. There was no adhe-
sion to adjacent organs and structures but a pinpoint
adhesion to the stomach. The right gastroepiploic artery
and vein were prominent and stretched by the tumor, and
a major supply vessel diverged from it in one stalk (Fig. 3).
There was no evidence of metastasis in the abdominal cav-
ity. Grossly, a well-demarcated reddish-gray solid tumor,
20 × 17 × 6 cm in size, showed irregular modularity (Fig
3). The cut surfaces were tan-colored and contained
focally necrotic areas and a cystic nodule. Histopatholog-
ically, the tumor was composed of proliferating epithe-
lioid cells and myxoid cells with an interlacing bundle
pattern (Fig. 4A &4B). The cellularity was relatively high
and the frequency of mitotic figures was 2 of 50 high
power fields (HPF). The MIB-1 index was 4.4% (Fig. 4D).
The tumor cells were diffusely immunoreactive for mye-
loid stem cell antigen (CD34), weakly or focally positive
for c-kit proto-oncogene protein product (CD117) (Fig.
4C) and slightly positive for neuron-specific enolase
(NSE). However, there was no staining for cytokeratin
(CK), alpha-smooth muscle actin (SMA) or S-100 protein.
Direct sequencing demonstrated mutations in the plate-
let-derived growth factor alpha (PDGFRA) gene exon 12,
codon 561, encoding a thymine to adenine substitution
(Fig. 5). These findings were consistent with a myxoid epi-
thelioid GIST lacking myogenic features and neural
attributes. The patient had a complete tumor resection
and an uneventful postoperative course. He was treated by
per os administration of Glevec® 300 mg/day as an adju-
vant postoperative molecular targeting chemotherapy and
has been living disease-free for 6 months.
Discussion
GISTs are mesenchymal tumors originating primarily
from interstitial cells of Cajal or related stem cell-like pre-
cursors [3] of the gastrointestinal tract wall. Typically, they
are characterized by the expression of the receptor tyro-
sine kinase Kit (CD117)[4], although some GISTs do not
or only weakly express this marker [5]. Primary omental
GISTs, Sakurai et al. implicated their possible pathogene-
sis from ICC-like Kit-positive cells existing in the normal
Computed TomographyFigure 1
Computed Tomography. A huge tumor behind the left 
hepatic lobe showed heterogeneous low density with faint 
enhancement. GB, gallbladder; GEA, gastroepiploic artery; T, 
tumor; PNC, pancreas; SPL, spleen.Page 2 of 5
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exclusive mutations in Kit or PDGFRA receptor tyrosine
kinase proteins play a central role in GIST pathogenesis
[7-10]. This is clearly illustrated by the collected data from
primary omental GISTs (Table 2). Mutually exclusive
gain-of-function Kit or PDGFRA mutations represent in-
frame deletions, point mutations, duplications or inser-
tions. Mutations in the Kit juxtamembrane domain (exon
11) are the most common in GISTs of all sites, whereas a
rare Kit extracellular domain (exon 9) Ala502-Tyr503
duplication is specific for intestinal GISTs. Mutations in
PDGFRA have been identified in the juxtamembrane
(exon 12), as observed in our case, and tyrosine kinase
domains (exons 14 and 18), nearly exclusively in gastric
GISTs, mostly epithelioid variants. Some Kit and PDGFRA
mutations carry prognostic value. The Kit/PDGFRA tyro-
sine kinase inhibitor Imatinib has been successfully used
in the treatment of metastatic GISTs for more than 5 years
[10,11]. Microscopic features are site-dependent and the
majority (more than 85%) appears as spindle cell tumors
[11,12]. However, only half of our collected omental
GISTs appeared to be spindle cell tumors, the remaining
being epithelioid and myxoid (Table 1). No correlation
between prognosis and histologic type has been reported.
On the other hand, it is well known that tumor size and
mitotic activity are the best prognostic features [10]. In
our case, the tumor size and the mitotic activity expressed
per 50 HPFs were 20 cm and 2, respectively. It is hardly
predict accurately the risk for disease progression and
malignant potential of our case, because of scarcity of the
primary omental GIST. Based on the criteria advocated by
Miettinen and Lasota, these two tumor parameters place
the tumor in group 3b, at the intermediate risk [10],
although according to the risk assessment proposed by
Fletcher, et al., our patient displayed high-risk feature
(tumor size above 10 cm, irrespective of low number of
mitoses) [13].
Because of possible relapse even after complete resection
of omental GISTs [14, 15, 16] and the objective response
rate of 67 % of Imatinib to the mutation in PDGFRA exon
12 [11], our patient received daily oral administration of
300 mg Glevec®, (we applied 15% reduced dose, referring
to a report by Cormier, et al. after took account of a
smaller average of Japanese build than American) [14,
16]. At the present time, there are no signs of toxicity and
no evidence of relapse. However, because of the short fol-
low-up period and rarity of the primary omental GISTs, it
is difficult to assess appropriately their malignant poten-
tial, efficacy of different treatment procedures and their
overall prognosis. In order to improve overall understand-
ing of the primary omental GISTs, it is useful to analyze
the collected detailed data from reported cases.
Conclusion
Our case demonstrated a weak immunohistochemical
expression of c-kit (CD117) and a point mutation in
PDGFRA exon 12 resulting in an Asp for Val561 substitu-
tion. Because of the rarity of primary omental GISTs, it is
difficult to assess their malignant potential and their over-
all prognosis. Imatinib therapy as an adjuvant to com-
plete resection has been carried out safely and may
prevent relapse to prolong long-term survival. It is essen-
tial to analyze accumulating data from case reports for a
better and more detailed understanding of primary omen-
tal GISTs.
Intra-operative photographFigure 3
Intra-operative photograph. Scissors indicate major 
tumor-feeding vessels (TFDV).
3-D reconstructed angiography of the gastroepiploic arteryFigu e 2
3-D reconstructed angiography of the gastroepiploic 
artery. A major tumor-supply artery diverges from the right 
gastroepiploic artery (REA).Page 3 of 5
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Genomic sequencing of the PDGFRA geneFigure 5
Genomic sequencing of the PDGFRA gene. Direct 
sequencing analysis showing a point mutation at codon 561 
(GTC to GAC) in exon12. Val561 is changed to Asp.
Photomicrographs of the primary omental GIST tumorFigure 4
Photomicrographs of the primary omental GIST 
tumor. A. Epithelioid components of GIST. Tumor cells 
show eosinophilic cytoplasm and peripherally placed nuclei, 
and are mostly cohesive (H&E). B. Some components show a 
spindle cell pattern with myxoid stroma (H&E). C. Tumor 
cells weakly immunoreactive for c-kit (CD117). D. Immunos-
taining for MIB-1: sparse of positive tumor cells are shown 
(MIB-1 index: 4.4%).
Table 1: Case review of the primary omental GISTs
Case No. Authors (Year) Age/Gender Size (cm) Histology Mitosis/50HPF Outcome
1 Takahashi [17] (1998) 71/M 17 Sp 1–3 ANED, 2-Mo
2 Miettinen [18] (1999) 58/F 2.5 Ep 1 Dead of colon cancer, 2.3-Yrs
3 89/M 2.5 Mixed 7 DUC, 3-Yrs
4 31/F 7.5 Sp 19 ANED, 3.5-Yrs
5 80/F 10 Ep 7 ANED, 2.0-Yrs
6 44/M 12 Ep <1 ANED, 1.6-Yrs
7 72/M 15 Mixed 26 ANED, 1.5-Yrs
8 67/F 16.5 Sp 5 LTF
9 56/F 20 Ep 0 LTF
10 64/M 20 Sp 4 ANED, 2.0-Yrs
11 34/M 23 Sp 1 LTF
12 60/M 24 Ep 1 ANED, 3.4-Yrs
13 68/F 26 Sp 2 ANED, 8.5-Yrs
14 70/F 36 Ep <1 LTF
15 Sakurai [6] (2001) 39/F 6 Sp 7.7** NA
16 52/F 11.5 Sp 4.3** NA
17 74/F 8 Sp <1** NA
18 65/F 16 Sp 0.9** NA
19 61/F 23 Sp 22** NA
20 Fukuda [19] (2001) 45/M 4.5 Sp <1* ANED, 0.9-Yrs
21 Suzuki [15] (2003) 65/M 13 Sp 5–8 13.8* DOD 1.3-Yrs (Liver mets.)
22 Sakurai [8] (2004) 73/F 4 Myxoid 3* ANED, 4-Mo
23 52/M >20 Ep 4* ANED, 13-Mo
24 Yamamoto [9](2004) 62/F 11 Ep 3 ANED, 0.5-Yrs
25 54//M 15 Ep 3 ANED, 5.2-Yrs
26 49/F 17 Ep 1 ANED, 4.0-Yrs
27 Caricato [20] (2005) 84/F ≤5 Sp NA ANED, 0.3-Yrs
28 Present case (2006) 65/M 20 Myxoid 2 ANED, 0.5-Yrs
Ep: epithelioid, SP: spindle, ANED: alive with no evident disease, Mo: month, Yrs: years, DUC: Dead of unknown cause, *: MIB-1-labeling index. **: 
K-67 labeling index (%), LFT: lost to follow-up, NA: not available, DOD: dead of disease,
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Table 2: Immunohistochemistry and Mutations in the primary omental GISTs
Case No. Histology Immunohistochemistry Mutations
KIT CD34 S100 SMA Desmin Gene Site
15 Spindle Positive + - - - C-kit Exon11, MS
16 Spindle Positive + - - - C-kit Exon11, IFD
17 Spindle Positive + - - - C-kit Exon11, MS
18 Spindle Positive + - - - C-kit Exon11, MS
19 Spindle Positive + - Weak - C-kit Exon11, IFD
22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del D842V
23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845
26 Epithelioid Weak + NA NA NA PDGFRA Exon18
28 Myxoid epithelioid Weak + - - - PDGFRA Exon12, V561D
MS: miss sense, IFD: in-frame deletion, NA: not availablePage 5 of 5
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